Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annu...( M.D. Anderson Cleveland Clinic Amo...),Health

M.D. Anderson, Cleveland Clinic Among Group of Leading Cancer Centers

Presenting Cryoablation Data

IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that cryoablation, a minimally invasive method of freezing cancerous tumors to destroy them, was the focus of 17 clinical studies presented at the six-day annual meeting of the American Urological Association (AUA) in Orlando, which is the largest urology meeting of the year.

Also, a total of six post-graduate educational courses and workshops related to cryoablation were sponsored by the AUA and, for the first time, the AUA adopted a specific set of prostate cancer clinical guidelines for cryoablation. A panel, led by Richard J. Babaian M.D. professor and senior medical director at M.D. Anderson Physician Network, announced a set of best practice statements for primary cryoablation, salvage cryoablation and focal cryoablation.

"The positive outcomes cryoablation has had for thousands of patients were evident in a variety of clinical studies presented by leading physicians and researchers throughout this year's AUA annual meeting," said Endocare Chairman, CEO and President Craig T. Davenport. "The breadth of attention that the AUA now pays to cryoablation, including educational courses, workshops and the adoption of AUA-sponsored clinical guidelines, underscores the acceptance of cryoablation as a safe and effective, minimally invasive treatment for prostate cancer and kidney cancer."

Highlights from the 17 stu
'/>"/>